Tags » Pharma

Business Development Manager {Profile Description: B-Pharmacy, Bio-Medical, Microbiology with MBA/ BBA in Sales & Marketing 3-5 years of exposure in selling Pharma, Medical Devices and Diagnostics products.}

Hiring: Business Development Manager


Gender: Male

Should own vehicle

Job Role: Managing a team of Business Development Executives, generating leads through other sources than  Hospitals; – more clarity in Job Description… 406 more words


Americans pharmacy claims that they discovered the medicine for cancer from red pine which they further claim the availability only in the US and Mexican belts. 136 more words

Starting Weekly Bio Capital


My name is Claudio De-Fraja and today I will start this weekly blog. I know, there are thousands of blogs out there, but none of them satisfy what I am looking for. 109 more words

FDA approves first ever drug for rare skin cancer

EMD Serono’s Bavencio (avelumab) has been granted accelerated approval by the FDA for the treatment of Merkel cell carcinoma (MCC), making it the first of its kind approved by the agency for the disease.  397 more words


Labeling Manager, Pharma, NJ - Katalyst HLS

Now Hiring – We have an immediate Full-Time Position available for Labeling Manager, Pharma with our client in NJ. The purpose of the position is to prepare corporate, US and EU labeling (prescribing information, patient information and other required labeling components) documents for developmental, mature and marketed products to obtain company and/or agency approval. 57 more words

Following a knee replacement surgery, that Henry Ford would have approved of, (Much of it was mechanized and all of it organized assembly line fashion) my wife ran almost instantly afoul of big pharma. 400 more words

Lilly's abemaciclib provides positive data, plans for NDA later this year

Eli Lilly’s experimental breast cancer combination has reached its primary endpoint in a key phase 3 trial investigating its use in advanced disease. 

The MONARCH 2 trial compared the combination of abemaciclib (LY2835219) plus fulvestrant (AstraZeneca’s Faslodex) to placebo plus fulvestrant in 669 intent-to-treat breast cancer patients. 284 more words